Pasithea Therapeutics Corp. (KTTA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders and RASopathies. The company's primary asset is PAS-004, a next-generation MEK inhibitor currently in Phase 1 clinical trials for advanced tumors and neurofibromatosis type 1 (NF1). The company discontinued its Clinics segment and PAS-002 (multiple sclerosis) program in 2023.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | Balance Sheet (Sep 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,999,834) | $(10,726,923) | N/A |
| Operating Loss | $(3,004,604) | $(10,990,412) | N/A |
| Cash & Equivalents | N/A | N/A | $9,361,169 |
| Working Capital | N/A | N/A | $9,118,375 |
| Accumulated Deficit | N/A | N/A | $(46,405,117) |
| Net Cash Used in Operations | N/A | $(11,480,402) | N/A |
Material Changes vs. Prior Period
- Operating Expenses: General and Administrative (G&A) expenses decreased by 34% ($741k) in Q3 2024 compared to Q3 2023, driven by lower legal and public company costs. Research and Development (R&D) expenses decreased slightly by 3% ($43k) in Q3 2024 due to the closure of the research laboratory, offset by increased clinical trial costs for PAS-004.
- YTD Trends: For the nine months ended September 30, 2024, R&D expenses increased by 20% ($939k) year-over-year, primarily due to the initiation of the Phase 1 clinical trial for PAS-004.
- Capital Raise: In late September 2024, the company completed a private placement (September 2024 Offering) raising approximately $4.5 million in gross proceeds through the sale of pre-funded warrants and PIPE warrants.
- Discontinued Operations: The company reported no loss from discontinued operations in 2024, compared to a loss of $437,015 in the same period in 2023.
Outlook, Risks, and Management Commentary
- Liquidity & Going Concern: Management explicitly states there is substantial doubt about the company's ability to continue as a going concern for twelve months from the filing date without additional funding. As of September 30, 2024, cash reserves of ~$9.4 million are insufficient to meet future needs.
- Clinical Progress: The company announced the successful completion of long-term chronic toxicity studies for PAS-004 and released preliminary safety and efficacy data from the first two cohorts of its Phase 1 trial. Plans include opening additional clinical sites in Eastern Europe in Q4 2024.
- Personnel Changes: Dr. Graeme Currie resigned as Chief Development Officer effective November 15, 2024. The company intends to proceed with clinical development using existing consultants.
- Internal Controls: The company disclosed a material weakness in internal controls related to the review of the annual income tax provision. Management is implementing remediation steps, including engaging a tax professional.
- Warrant Liability: The company recorded a loss of $70,306 in Q3 2024 due to changes in the fair value of warrant liabilities.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion given the "substantial doubt" disclosure and the recent $4.5M raise.
- Capital Requirements: Assess the cost to complete the Phase 1/2a trials for PAS-004 and the likelihood of securing further equity or debt financing.
- Dilution Risk: Review the terms of the September 2024 Offering (pre-funded warrants and PIPE warrants) and the impact of the 1:20 reverse stock split on share count and option/warrant exercise prices.
- Clinical Data: Monitor the release of full Phase 1 data for PAS-004 and the timeline for opening Eastern European sites.
- Internal Controls: Track the remediation progress of the material weakness regarding tax provision disclosures.